CTOs on the Move

www.sperohealth.com

www.Spero Health

 
Spero Health, Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders with a mission to “Save Lives, Instill Hope, and Restore Relationships.” Spero Health utilizes an innovative evidenced-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.Spero Health
  • 5141 Virginia Way
    Brentwood, TN USA 37027
  • Phone: 859.209.2377

Executives

Name Title Contact Details

Similar Companies

Htv Systems

Htv Systems Ltd is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Responselink

Responselink is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jero Medical Equipment and Supplies Inc

Jero Medical Equipment and Supplies Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mobility Works

Mobility Works is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.